1-磷酸鞘氨醇在冠心病合并阻塞性睡眠呼吸暂停综合征患者血清中的表达及其意义-现代医学

1-磷酸鞘氨醇在冠心病合并阻塞性睡眠呼吸暂停综合征患者血清中的表达及其意义

单位：1. 东南大学附属中大医院心血管内科, 江苏南京 210009;
2. 东南大学医学院, 江苏南京 210009

分类号：R541

出版年·卷·期（页码）：2021·49·第十二期（1437-1440）

摘要：

目的： 探讨冠状动脉粥样硬化性心脏病（CHD）合并阻塞性睡眠呼吸暂停综合征（OSAS）患者血清1-磷酸鞘氨醇（S1P）的水平变化及其临床意义。方法： 选取2015年4月至2016年12月东南大学附属中大医院以CHD或胸闷胸痛查因为初诊诊断且合并鼾症的患者80例为研究对象。根据冠状动脉造影术结果分为CHD组45例和无CHD组35例，再根据多导睡眠监测检查结果分为重度OSAS、中度OSAS、轻度OSAS及无OSAS，比较CHD合并OSAS患者血清S1P水平。结果： CHD组患者血清S1P水平（4 553±1 812 nmol·L^-1）高于无CHD组（2 694±1 305 nmol·L^-1），差异有统计学意义（P<0.01）；和无OSAS患者相比，合并OSAS患者的S1P水平显著升高，且随着OSAS严重程度的加重，S1P呈上升趋势，差异有统计学意义（P<0.01）。结论： OSAS可能通过增加S1P的水平来促进CHD的发生发展。

Objective: To investigate the role of sphingosine-1-phosphate (S1P) in patients with coronary heart disease (CHD) complicated with obstructive sleep apnea hyponea syndrome (OSAS)and to explore the changes of serum S1P levels in patients with CHD and OSAS. Methods: We collected 80 patients with CHD or chest tightness and chest pain in Zhongda Hospital from April 2015 to December 2016.All the patients complicated with snoring. According to the results of coronary angiography, the subjects were divided into CHD group (45 cases) and no CHD group (35 cases).Then each group was divided into four subgroups:severe OSAS, moderate OSAS, mild OSAS and no OSAS according to the results of polysomnography. The serum S1P levels of patients in each group were compared. Results: The level of serum S1P in the CHD group(4 553±1 812 nmol·L^-1)was higher than that in the non-CHD group (2 694±1 305 nmol·L^-1), the difference was statistically significant (P<0.01). In addition, with the severity of OSAS, S1P showed an upward trend for OSAS patients. Conclusion: OSAS may affect the occurrence and development of CHD by affecting the level of S1P.

参考文献：

[1] MAEDER M T,SCHOCH O D,RICHLI H.A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease[J].Vasc Health Risk Manag,2016,12:85-103.
[2] DRAGER L F,MCEVOY R D,BARBE F,et al.Sleep apnea and cardiovascular disease:lessons from recent trials and need for team science[J].Circulation,2017,136(19):1840-1850.
[3] SELIM S,SUNKARA M,SALOUS A K,et al.Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit,but variably restored by red blood cell transfusions[J].Clin Sci (Lond),2011,121(12):565-572.
[4] SUGIURA T,DOHI Y,YAMASHITA S,et al.Analytical evaluation of plasma serotonin and sphingosine 1-phosphate and their clinical assessment in early atherosclerosis[J].Coron Artery Dis,2012,23(4):234-238.
[5] GOZAL D.Pediatric OSA:a case for "united we stand" in the way of a breath[J].Pediatr Pulmonol,2010,45(12):1151-1152.
[6] 中华医学会呼吸病学分会睡眠呼吸疾病学组.阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J].中华结核和呼吸杂志,2011,35(1):594-597.
[7] INONU K H,PAZARLI A C,KANBAY A,et al.Monocyte count/HDL cholesterol ratio and cardiovascular disease in patients with obstructive sleep apnea syndrome:a multicenter study[J].Clin Appl Thromb Hemost,2018,24(1):139-144.
[8] 吴悦陶,刘瑞洪.阻塞型睡眠呼吸暂停综合征与动脉粥样硬化[J].临床与病理杂志,2007,27(4):324-327.
[9] BERGER S,LAVIE L.Endothelial progenitor cells in cardiovascular disease and hypoxia——potential implications to obstructive sleep apnea[J].Transl Res,2011,158(1):1-13.
[10] CARPAGNANO G E,SPANEVWLLO A,SABATO R,et al.Systemic and airway inflammation in sleep apnea and obesity:the role of ICAM-1 and IL-8[J].Transl Res,2010,155(1):35-43.
[11] MANDAL S,KENT B D.Obstructive sleep apnoea and coronary artery disease[J].J Thorac Dis,2018,10(S34):S4212-S4220.
[12] COELHO F M,PRADELLA-HALLINAN M,PALOMBINI L,et a1.The STOP-BANG questionnaire was a useful tool to identify OSA during epidemiological study in Sao Paulo(Brazil)[J].Sleep Med,2012,13(4):450-451.
[13] LEVY P,TAMISIER R,ARNAUD C,et al.Sleep deprivation,sleep apnea and cardiovascular diseases[J].Front Biosci,2012,4(6):2007-2021.
[14] HAO W,WANG X,FAN J,et al.Association between apnea-hypopnea index and coronary artery calcification:a systematic review and meta-analysis[J].Ann Med,2021,53(1):302-317.
[15] SATTLER K J,ELBASAN S,KEUL P,et al.Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease[J].Basic Res Cardiol,2010,105(6):821-832.
[16] ARGRAVES K M,GAZZOLO P J,GROH E M,et al.High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function[J].J Biol Chem,2008,283(36):25074-25081.
[17] DEUTSCHMAN D H,CARSTENS J S,KLEPPER R L,et al.Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate[J].Am Heart J,2003,146(1):62-68.
[18] 贺苗,赵杰,苏健,等.1-磷酸鞘氨醇后适应对大鼠心肌缺血/再灌注损伤的保护作用[J].中国药理学通报,2013,29(10):1369-1373.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录